

SEQUENCE LISTING

<110> Biochemical and Pharmacological Laboratories Inc.

<120> A screening method for physiologically active substance

<130> 03-061-PCT

<160> 9

<210> 1

<211> 138

<212> PRT

<213> Homo sapiens

<400> 1

Met Gln Leu Glu Ile Gln Val Ala Leu Asn Phe Ile Ile Ser Tyr Leu
1 5 10 15

Tyr Asn Lys Leu Pro Arg Arg Arg Val Asn Ile Phe Gly Glu Glu Leu
20 25 30

Glu Arg Leu Leu Lys Lys Lys Tyr Glu Gly His Trp Tyr Pro Glu Lys
35 40 45

Pro Tyr Lys Gly Ser Gly Phe Arg Cys Ile His Ile Gly Glu Lys Val
50 55 60

Asp Pro Val Ile Glu Gln Ala Ser Lys Glu Ser Gly Leu Asp Ile Asp
65 70 75 80

Asp Val Arg Gly Asn Leu Pro Gln Asp Leu Ser Val Trp Ile Asp Pro
85 90 95

Phe Glu Val Ser Tyr Gln Ile Gly Glu Lys Gly Pro Val Lys Val Leu
100 105 110

Tyr Val Asp Asp Asn Asn Glu Asn Gly Cys Glu Leu Asp Lys Glu Ile
115 120 125

Lys Asn Ser Phe Asn Pro Glu Ala Gln Val
130 135

<210> 2

<211> 19

<212> PRT

<213> Homo sapiens

<400> 2

Tyr	Glu	Gly	His	Trp	Tyr	Pro	Glu	Lys	Pro	Tyr	Lys	Gly	Ser	Gly	Phe
1				5					10					15	

Arg Cys Ile

<210> 3

<211> 21

<212> PRT

<213> Homo sapiens

<400> 3

Leu	Pro	Gln	Asp	Leu	Ser	Val	Trp	Ile	Asp	Pro	Phe	Glu	Val	Ser	Tyr
1				5					10					15	

Gln Ile Gly Glu Lys
20

<210> 4

<211> 285

<212> PRT

<213> Homo sapiens

<400> 4

Met	Pro	Ala	Glu	Thr	Val	Asp	His	Ser	Gln	Arg	Ile	Cys	Glu	Val	Trp
1				5					10					15	

Ala	Cys	Asn	Leu	Asp	Glu	Glu	Met	Lys	Lys	Ile	Arg	Gln	Val	Ile	Arg
			20					25						30	

Lys	Tyr	Asn	Tyr	Val	Ala	Met	Asp	Thr	Glu	Phe	Pro	Gly	Val	Val	Ala
		35					40					45			

Arg	Pro	Ile	Gly	Glu	Phe	Arg	Ser	Asn	Ala	Asp	Tyr	Gln	Tyr	Gln	Leu
	50					55					60				

Leu	Arg	Cys	Asn	Val	Asp	Leu	Leu	Lys	Ile	Ile	Gln	Leu	Gly	Leu	Thr
65				70					75					80	

Phe Met Asn Glu Gln Gly Glu Tyr Pro Pro Gly Thr Ser Thr Trp Gln

	85	90	95
Phe Asn Phe Lys Phe Asn Leu Thr Glu Asp Met Tyr Ala Gln Asp Ser			
	100	105	110
Ile Glu Leu Leu Thr Thr Ser Gly Ile Gln Phe Lys Lys His Glu Glu			
	115	120	125
Glu Gly Ile Glu Thr Gln Tyr Phe Ala Glu Leu Leu Met Thr Ser Gly			
	130	135	140
Val Val Leu Cys Glu Gly Val Lys Trp Leu Ser Phe His Ser Gly Tyr			
	145	150	155
Asp Phe Gly Tyr Leu Ile Lys Ile Leu Thr Asn Ser Asn Leu Pro Glu			
	165	170	175
Glu Glu Leu Asp Phe Phe Glu Ile Leu Arg Leu Phe Phe Pro Val Ile			
	180	185	190
Tyr Asp Val Lys Tyr Leu Met Lys Ser Cys Lys Asn Leu Lys Gly Gly			
	195	200	205
Leu Gln Glu Val Ala Glu Gln Leu Glu Leu Glu Arg Ile Gly Pro Gln			
	210	215	220
His Gln Ala Gly Ser Asp Ser Leu Leu Thr Gly Met Ala Phe Phe Lys			
	225	230	235
Met Arg Glu Met Phe Phe Glu Asp His Ile Asp Asp Ala Lys Tyr Cys			
	245	250	255
Gly His Leu Tyr Gly Leu Gly Ser Gly Ser Ser Tyr Val Gln Asn Gly			
	260	265	270
Thr Gly Asn Ala Tyr Glu Glu Glu Ala Asn Lys Gln Ser			
	275	280	

<210> 5
 <211> 30
 <212> DNA
 <213> Artificial Sequence

 <220>

<223> PCR primer to amplify *tob* gene

<400> 5

cccggatcca tgcagcttga aatccaagta

30

<210> 6

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer to amplify *tob* gene

<400> 6

cccgtcgacg ttagccataa caggctggaa

30

<210> 7

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer to amplify *lck* gene

<400> 7

atgggctgtg gctgcagctc a

21

<210> 8

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer to amplify *lck* gene

<400> 8

cccgtcgaca ggctgaggct ggtactggcc

30

<210> 9

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer to amplify *lckYF* gene

<400> 9

cccgtcgaca ggctgaggct gaaactggcc

30